Payment & Shipping Terms | Supply Capacity |
Payment Terms: | T/T, WU | Production Capacity: | 1kg/year |
Min. Order: | 1 Gram | Packing: | according to the customer's requirements |
Means of Transport: | Ocean, Air, Land | Delivery Date: | 7 days |
Palbociclib
CAS: 571190-30-2
Palbociclib, a new breast cancer drug developed by Pfizer in the United States, is marketed as IBRANCE, an oral cyclin-dependent kinase (CDKs) 4 and 6 inhibitor, the first cyclin-dependent kinase 4/6 (cdk4/6) inhibitor approved by the us FDA. CDKs4 and 6 are key regulators of cell cycle and can trigger cell cycle progression. IBRANCE is indicated in the United States for the combination of letrozole for the treatment of estrogen receptor-positive, and human epidermal growth factor receptor-negative (ER+/ her2-negative) postmenopausal advanced breast cancer patients, as an initial endocrine-based regimen for the treatment of metastatic diseases.
We can customize according to customer's requirement
if you have any question pls mail us or call us
